Abstract
Verapamil, usually given as a racemic mixture, decreases in vivo and in vitro digoxin renal tubular secretion, which is suggested to be mediated by P-glycoprotein, an ATP-dependent multidrug efflux pump. Importantly, the two enantiomers of verapamil have been reported to similarly inhibit P-glycoprotein-mediated transport of chemotherapeutic agents. In this study, we examined effects of enantiomers of verapamil on digoxin transport across an LLC-PK1 cell monolayer, a model of proximal renal tubular cells. The results indicate that verapamil inhibition of digoxin transport is non-stereospecific. Furthermore, the verapamil-digoxin interaction is not competitive. The two drugs may not share a common initial step in the P-glycoprotein-mediated transport.
| Original language | English |
|---|---|
| Pages (from-to) | PL399-PL403 |
| Journal | Life Sciences |
| Volume | 53 |
| Issue number | 24 |
| DOIs | |
| State | Published - 1993 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver